Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ADBE
2. SPCX
3. USO
4. SPY
5. RH
6. NVDA
7. RKLB
8. CRM
9. MSFT
10. DOL:CN

Go back to Arbutus Receives U.S. FDA Fast Track Designation for Imdusiran for the Treatment of Chronic Hepatitis B
(NASDAQ: ABUS) Delayed: 4.26 -0.03 (0.7%)
Previous Close $4.29    52 Week High $5.88 
Open $4.27    52 Week Low $2.65 
Day High $4.33    P/E N/A 
Day Low $4.25    EPS $0.00 
Volume 1,011,474       

(NASDAQ: ABUS) Delayed: 4.26 -0.03 (0.7%)
Previous Close $4.29    52 Week High $5.88 
Open $4.27    52 Week Low $2.65 
Day High $4.33    P/E N/A 
Day Low $4.25    EPS $0.00 
Volume 1,011,474